[
    {
        "molecule_name": "Apalutamide",
        "protein_target_name": "AR",
        "binding_metric": "Kd",
        "value": "0.5",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Enzalutamide",
        "protein_target_name": "AR",
        "binding_metric": "Kd",
        "value": "0.64",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Apalutamide",
        "protein_target_name": "AR",
        "binding_metric": "Ki",
        "value": "18.07",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Apalutamide",
        "protein_target_name": "AR-F876L",
        "binding_metric": "Ki",
        "value": "0.68",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Enzalutamide",
        "protein_target_name": "AR",
        "binding_metric": "Ki",
        "value": "26.30",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Enzalutamide",
        "protein_target_name": "AR-F876L",
        "binding_metric": "Ki",
        "value": "0.60",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Bicalutamide",
        "protein_target_name": "AR",
        "binding_metric": "Ki",
        "value": "26.56",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Bicalutamide",
        "protein_target_name": "AR-F876L",
        "binding_metric": "Ki",
        "value": "360",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Hydroxyflutamide",
        "protein_target_name": "AR",
        "binding_metric": "Ki",
        "value": "14.56",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Hydroxyflutamide",
        "protein_target_name": "AR-F876L",
        "binding_metric": "Ki",
        "value": "150",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Nilutamide",
        "protein_target_name": "AR",
        "binding_metric": "Ki",
        "value": "17.74",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Nilutamide",
        "protein_target_name": "AR-F876L",
        "binding_metric": "Ki",
        "value": "197.42",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Methyltrienolone",
        "protein_target_name": "AR",
        "binding_metric": "Kd",
        "value": "0.5",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    },
    {
        "molecule_name": "Methyltrienolone",
        "protein_target_name": "AR-F877L",
        "binding_metric": "Kd",
        "value": "0.64",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nARN-509 and enzalutamide bound the mutant with 30 and 48-fold higher affinity, respectively (Table 8, Figure 5) (Kd for R1881: AR = 0.5 nM; AR-F877L = 0.64 nM).\nTable 8.CompoundAR binding, WT K<sub>i</sub> (nM)AR binding, F876L K<sub>i</sub> (nM)ARN-50918.07 ± 7.460.68 ± 0.15Enzalutamide26.30 ± 12.770.60 ±0.17Bicalutamide26.56 ± 12.51360.36 ± 283.85Hydroxyflutamide14.56 ± 8.25150.57 ± 55.10Nilutamide17.74 ± 5.65197.42 ± 9.26\nKi was calculated as Ki = IC50/(1 + ([<sup>3</sup>H-R1881]/Kd)), [<sup>3</sup>H-R1881] = 0.6 nM.\nFor endogenous target gene analysis, LNCaP/AR(cs), LNCaP SRαF876L, and LNCaP/pCDNAF876L cells were cultured for 3 days in hormone depleted medium followed by treatment with vehicle, 1 nM R1881 or 1, 3, 10 and 30 µM ARN-509 or enzalutamide in the presence or absence on 1 nM R1881."
    }
]